Filter posts

We Heart GMOs, Science, and Technology: What We’re Reading, February 2017

Each month, GMO Answers compiles a few stories we think particularly noteworthy. With February being …

Alzheimer’s Research: Where We’ve Failed and What’s To Come

Alzheimer’s disease is a rapidly growing public health crisis. Today an estimated 5.4 million Americans …

“Please Wait a Few Moments While Your Pill Prints”

Since the late 1980’s, innovators have dreamed of living in a world where science could …

FDA Acts on Biosimilars

The Biologics Price Competition and Innovation Act (BPCIA) deferred to the Food and Drug Administration …

BIO Is Almost Here – What To Consider Before Entering New Therapeutic Areas

Over the past decade, the biopharmaceutical industry has witnessed a shift towards specialty care. From …

New PhRMA report: Nearly 800 Cancer Medicines in Development

A new report from the Pharmaceutical Research and Manufacturers of America (PhRMA) shows that biopharma …

Tekmira Pharmaceuticals Ebola Drug Gets Nod From FDA

The U.S. Food and Drug Administration has authorized Canada’s Tekmira Pharmaceuticals to provide an experimental drug …

Chicago Tribune Makes a Case for GMOs

The editorial board of the Chicago Tribune recently wrote a great piece arguing why this state-by-state …

U.S. Rep. Charlie Dent Discusses PDUFA and NIH Funding at #BIOCEO14

During the 16th Annual BIO CEO & Investor Conference, U.S. Representative Charlie Dent of Pennsylvania, …

National Traceability System Moves into Implementation

Last week, President Obama signed into law the Drug Quality and Security Act (H.R. 3204), …